voclosporin lupus nephritis
Selected indexed studies
- Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (Lancet, 2021) [PMID:33971155]
- Systemic Lupus Erythematosus: A Review. (JAMA, 2024) [PMID:38587826]
- Lupus Nephritis from Pathogenesis to New Therapies: An Update. (Int J Mol Sci, 2024) [PMID:39201667]
_Worker-drafted node — pending editorial review._
Connections
voclosporin lupus nephritis is a side effect of
Sources
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. (2024) pubmed
- Systemic Lupus Erythematosus: A Review. (2024) pubmed
- Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (2021) pubmed
- Lupus Nephritis from Pathogenesis to New Therapies: An Update. (2024) pubmed
- Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. (2024) pubmed
- Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria. (2024) pubmed
- Voclosporin (Lupkynis) for lupus nephritis. (2021) pubmed
- Lupus Nephritis in Children: Novel Perspectives. (2023) pubmed
- An evaluation of voclosporin for the treatment of lupus nephritis. (2018) pubmed
- PMID:40127165 (2023) pubmed